- Global Pharma News & Resources

Worldwide Acquired Hemophilia Drugs Industry to 2027 - by Type, Treatment, Therapy, Distribution Channel and Region -

DUBLIN--(BUSINESS WIRE)--The "Acquired Hemophilia Drugs Market 2021-2027" report has been added to's offering.

The global acquired hemophilia drugs market is anticipated to grow at a considerable CAGR during the forecast period.

The major factors driving the growth of the market include the rising burden of rare disorder among population globally, increasing awareness of hemophilia, and government contribution towards prevention and control of such disease. Moreover, significant investment by key pharmaceutical companies in R&D of novel therapies for hemophilia is also propelling the expansion of market growth.

The global acquired hemophilia drugs market is segmented based on type, treatment, therapy, and distribution channel. Based on type, the market is sub-segmented into hemophilia A, hemophilia B, and hemophilia C. On the basis of treatment, the market is sub-segmented into on-demand and prophylaxis. Based on therapy, the market is sub-categorized into replacement therapy, ITI therapy, and gene therapy. On the basis of distribution channel, the market is sub-segmented into hospital pharmacy, online pharmacy, and retail pharmacy.

Geographically, the global acquired hemophilia drugs market covers the analysis of four major regions including North America (the US and Canada), Europe (UK, Germany, Italy, Spain, France, and Rest of Europe), Asia-Pacific (China, Japan, India, and Rest of Asia-Pacific), and the Rest of the World.

Companies Mentioned

  • Aptevo Therapeutics
  • Bayer AG
  • CSL Behring
  • Genzyme Corp.
  • Grifols SA
  • F. Hoffman La Roche Ltd.
  • Octapharma AG
  • Pfizer Inc
  • Spark Therapeutics, Inc.
  • Takeda Pharmaceutical Co. Ltd.

The Report Covers

  • Comprehensive research methodology of the global acquired hemophilia drugs market.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the global acquired hemophilia drugs market.
  • Insights about market determinants that are stimulating the global acquired hemophilia Drugs market.
  • Detailed and extensive market segments with the regional distribution of forecasted revenues.
  • Extensive profiles and recent developments of market players.

Key Topics Covered:

1. Report Summary

2. Market Overview and Insights

2.1. Scope of the Report

2.2. Analyst Insight & Current Market Trends

2.2.1. Key Findings

2.2.2. Recommendations

2.2.3. Conclusion

3. Market Determinants

3.1. Motivators

3.2. Restraints

3.3. Opportunities

4. Market Segmentation

4.1. Global Acquired Hemophilia Drugs Market by Type

4.1.1. Hemophilia A

4.1.2. Hemophilia B

4.1.3. Hemophilia C

4.2. Global Acquired Hemophilia Drugs Market by Treatment

4.2.1. On-Demand

4.2.2. Prophylaxis

4.3. Global Acquired Hemophilia Drugs Market by Therapy

4.3.1. Replacement Therapy

4.3.2. ITI Therapy

4.3.3. Gene Therapy

4.4. Global Acquired Hemophilia Drugs Market by Distribution Channel

4.4.1. Hospital Pharmacy

4.4.2. Online Pharmacy

4.4.3. Retail Pharmacy

5. Regional Analysis

5.1. North America

5.1.1. United States

5.1.2. Canada

5.2. Europe

5.2.1. UK

5.2.2. Germany

5.2.3. Italy

5.2.4. Spain

5.2.5. France

5.2.6. Rest of Europe

5.3. Asia-Pacific

5.3.1. China

5.3.2. India

5.3.3. Japan

5.3.4. Rest of Asia-Pacific

5.4. Rest of the World

6. Company Profiles

6.1. Aptevo Therapeutics

6.2. Bayer AG

6.3. CSL Behring

6.4. Genzyme Corp.

6.5. Grifols SA

6.6. F. Hoffman La Roche Ltd.

6.7. Octapharma AG

6.8. Pfizer Inc

6.9. Spark Therapeutics, Inc

6.10. Takeda Pharmaceutical Co. Ltd.

For more information about this report visit

Laura Wood, Senior Press Manager

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Editor Details

  • Company:
    • Businesswire
Last Updated: 01-Jun-2022